Citius Oncology, Inc.: 10-Q filed 2025-05-14
What Citius Oncology, Inc. reported in its quarterly report filed 2025-05-14 (fiscal Q2 2025): 26 published measures, 76 facts as tagged in accession 0001213900-25-043359.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-05-14
- Fiscal period
- fiscal Q2 2025
- Accession
- 0001213900-25-043359 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Oncology, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 91,439,365 | USD | |
| At 2024-09-30 | 84,368,878 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 55,796,733 | USD | |
| At 2024-09-30 | 38,228,539 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 35,642,632 | USD | |
| At 2024-12-31 | 41,289,612 | USD | |
| At 2024-09-30 | 46,140,339 | USD | |
| At 2024-03-31 | 19,846,711 | USD | |
| At 2023-12-31 | 22,725,257 | USD | |
| At 2023-09-30 | 25,535,660 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 112 | USD | |
| At 2024-09-30 | 112 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -7,735,552 | USD | 90 |
| 2024-10-01 to 2025-03-31 | -14,394,757 | USD | 182 |
| 2024-10-01 to 2024-12-31 | -6,659,205 | USD | 92 |
| 2024-01-01 to 2024-03-31 | -4,835,546 | USD | 91 |
| 2023-10-01 to 2024-03-31 | -9,562,949 | USD | 183 |
| 2023-10-01 to 2023-12-31 | -4,727,403 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | -53,673,344 | USD | |
| At 2024-09-30 | -39,278,587 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 71,552,402 | shares | 90 |
| 2024-10-01 to 2025-03-31 | 71,552,402 | shares | 182 |
| 2024-01-01 to 2024-03-31 | 67,500,000 | shares | 91 |
| 2023-10-01 to 2024-03-31 | 67,500,000 | shares | 183 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 71,552,402 | shares | 90 |
| 2024-10-01 to 2025-03-31 | 71,552,402 | shares | 182 |
| 2024-01-01 to 2024-03-31 | 67,500,000 | shares | 91 |
| 2023-10-01 to 2024-03-31 | 67,500,000 | shares | 183 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -0.11 | USD/shares | 90 |
| 2024-10-01 to 2025-03-31 | -0.2 | USD/shares | 182 |
| 2024-01-01 to 2024-03-31 | -0.07 | USD/shares | 91 |
| 2023-10-01 to 2024-03-31 | -0.14 | USD/shares | 183 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -0.11 | USD/shares | 90 |
| 2024-10-01 to 2025-03-31 | -0.2 | USD/shares | 182 |
| 2024-01-01 to 2024-03-31 | -0.07 | USD/shares | 91 |
| 2023-10-01 to 2024-03-31 | -0.14 | USD/shares | 183 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 264,240 | USD | 90 |
| 2024-10-01 to 2025-03-31 | 528,480 | USD | 182 |
| 2024-01-01 to 2024-03-31 | 144,000 | USD | 91 |
| 2023-10-01 to 2024-03-31 | 288,000 | USD | 183 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-10-01 to 2025-03-31 | 3,897,050 | USD | 182 |
| 2023-10-01 to 2024-03-31 | 3,874,000 | USD | 183 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 18,039,365 | USD | |
| At 2024-09-30 | 10,968,878 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 49,740,142 | USD | |
| At 2024-09-30 | 32,700,428 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 7,676,310 | USD | |
| At 2024-09-30 | 3,711,622 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 7,471,312 | USD | 90 |
| 2024-10-01 to 2025-03-31 | 13,866,277 | USD | 182 |
| 2024-01-01 to 2024-03-31 | 4,691,546 | USD | 91 |
| 2023-10-01 to 2024-03-31 | 9,274,949 | USD | 183 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 15,339,253 | USD | |
| At 2024-09-30 | 8,268,766 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 3,139,413 | USD | 90 |
| 2024-10-01 to 2025-03-31 | 4,403,921 | USD | 182 |
| 2024-01-01 to 2024-03-31 | 1,348,966 | USD | 91 |
| 2023-10-01 to 2024-03-31 | 2,497,461 | USD | 183 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 71,552,402 | shares | |
| At 2024-09-30 | 71,552,402 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 89,308,821 | USD | |
| At 2024-09-30 | 85,411,771 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 8,722,168 | USD |
Net deferred tax liabilities
Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 2,256,480 | USD | |
| At 2024-09-30 | 1,728,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -7,471,312 | USD | 90 |
| 2024-10-01 to 2025-03-31 | -13,866,277 | USD | 182 |
| 2024-01-01 to 2024-03-31 | -4,691,546 | USD | 91 |
| 2023-10-01 to 2024-03-31 | -9,274,949 | USD | 183 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 2,243,327 | USD | 90 |
| 2024-10-01 to 2025-03-31 | 5,565,306 | USD | 182 |
| 2024-01-01 to 2024-03-31 | 1,385,580 | USD | 91 |
| 2023-10-01 to 2024-03-31 | 2,903,488 | USD | 183 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-10-01 to 2025-03-31 | 528,480 | USD | 182 |
| 2023-10-01 to 2024-03-31 | 288,000 | USD | 183 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-10-01 to 2025-03-31 | 7,070,487 | USD | 182 |
Inspect the source
- Entity
- Citius Oncology, Inc. / CIK 0001851484
- Captured
- 2026-09-21T17:32:34.031Z
- SEC response SHA-256
1e8c39a029a9529c1971ba7b07551c1ef4dd6de443d807231887851f2cef037a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001851484.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))